Radiolabeled Iron Oxide Nanoparticles Functionalized with PSMA/BN Ligands for Dual-targeting of Prostate Cancer

Overview

Journal Front Nucl Med

Date 2024 Oct 9

PMID 39380961

Authors

Danae Efremia Bajwa

Evangelia-Alexandra Salvanou

Maria Theodosiou

Theodora S Koutsikou

Eleni K Efthimiadou

Penelope Bouziotis

Christos Liolios

Affiliations

Soon will be listed here.

Abstract

Introduction: Prostate cancer (PCa) is the second most frequent cancer diagnosis in men and the fifth leading cause of death worldwide. Prostate Specific Membrane Antigen (PSMA) and Gastrin Releasing Peptide (GRP) receptors are overexpressed in PCa. In this study, we have developed iron oxide nanoparticles (IONs) functionalized with the Prostate Specific Membrane Antigen (PSMA) and Gastrin Releasing Peptide (GRP) ligands for dual targeting of Prostate cancer.

Methods: IONs were developed with a thin silica layer on their surface with MPTES (carrying -SH groups, IONs-SH), and they were coupled either with a pharmacophore targeting PSMA (IONs-PSMA) or with bombesin peptide (IONs-BN), targeting GRP receptors, or with both (IONs-PSMA/BN). The functionalized IONs were characterized for their size, zeta potential, and efficiency of functionalization using dynamic light scattering (DLS) and Fourier-Transform Infrared Spectroscopy (FT-IR). All the aforementioned types of IONs were radiolabeled directly with Technetium-99m (Tc) and evaluated for their radiolabeling efficiency, stability, and binding ability on two different PCa cell lines (PC3 and LNCaP).

Results And Discussion: The MTT assay demonstrated low toxicity of the IONs against PC3 and LNCaP cells, while the performed wound-healing assay further proved that these nanostructures did not affect cellular growth mechanisms. The observed hemolysis ratio after co-incubation with red blood cells was extremely low. Furthermore, the Tc-radiolabeled IONs showed good stability in human serum, DTPA, and histidine, and high specific binding rates in cancer cells, supporting their future utilization as potential diagnostic tools for PCa with Single Photon Emission Computed Tomography (SPECT) imaging.

References

Malhotra N, Lee J, Liman R, Ruallo J, Villaflores O, Ger T . Potential Toxicity of Iron Oxide Magnetic Nanoparticles: A Review. Molecules. 2020; 25(14). PMC: 7397295. DOI: 10.3390/molecules25143159. View

Eder M, Schafer M, Bauder-Wust U, Hull W, Wangler C, Mier W . 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012; 23(4):688-97. DOI: 10.1021/bc200279b. View

Guo P, Huang J, Moses M . Cancer Nanomedicines in an Evolving Oncology Landscape. Trends Pharmacol Sci. 2020; 41(10):730-742. DOI: 10.1016/j.tips.2020.08.001. View

Chakravarty R, Goel S, Dash A, Cai W . Radiolabeled inorganic nanoparticles for positron emission tomography imaging of cancer: an overview. Q J Nucl Med Mol Imaging. 2017; 61(2):181-204. PMC: 5477426. DOI: 10.23736/S1824-4785.17.02969-7. View

Maurer T, Eiber M, Schwaiger M, Gschwend J . Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016; 13(4):226-35. DOI: 10.1038/nrurol.2016.26. View

Tsoukalas C, Psimadas D, Kastis G, Koutoulidis V, Harris A, Paravatou-Petsotas M . A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis. Front Chem. 2018; 6:224. PMC: 6019489. DOI: 10.3389/fchem.2018.00224. View

Gurunathan S, Kang M, Qasim M, Kim J . Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer. Int J Mol Sci. 2018; 19(10). PMC: 6214025. DOI: 10.3390/ijms19103264. View

Tsiapa I, Efthimiadou E, Fragogeorgi E, Loudos G, Varvarigou A, Bouziotis P . (99m)Tc-labeled aminosilane-coated iron oxide nanoparticles for molecular imaging of ανβ3-mediated tumor expression and feasibility for hyperthermia treatment. J Colloid Interface Sci. 2014; 433:163-175. DOI: 10.1016/j.jcis.2014.07.032. View

Apostolopoulou A, Chiotellis A, Salvanou E, Makrypidi K, Tsoukalas C, Kapiris F . Synthesis and In Vitro Evaluation of Gold Nanoparticles Functionalized with Thiol Ligands for Robust Radiolabeling with Tc. Nanomaterials (Basel). 2021; 11(9). PMC: 8471789. DOI: 10.3390/nano11092406. View

10.

Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V . Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008; 49(2):318-26. DOI: 10.2967/jnumed.107.045054. View

11.

Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W . Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med. 2015; 56(6):914-20. DOI: 10.2967/jnumed.114.147413. View

12.

Psimadas D, Baldi G, Ravagli C, Bouziotis P, Xanthopoulos S, Franchini M . Preliminary evaluation of a 99mTc labeled hybrid nanoparticle bearing a cobalt ferrite core: in vivo biodistribution. J Biomed Nanotechnol. 2012; 8(4):575-85. DOI: 10.1166/jbn.2012.1412. View

13.

Aghebati-Maleki A, Dolati S, Ahmadi M, Baghbanzhadeh A, Asadi M, Fotouhi A . Nanoparticles and cancer therapy: Perspectives for application of nanoparticles in the treatment of cancers. J Cell Physiol. 2019; 235(3):1962-1972. DOI: 10.1002/jcp.29126. View

14.

Gonzalez N, Moody T, Igarashi H, Ito T, Jensen R . Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes. 2008; 15(1):58-64. PMC: 2631407. DOI: 10.1097/MED.0b013e3282f3709b. View

15.

Salvanou E, Stellas D, Tsoukalas C, Mavroidi B, Paravatou-Petsotas M, Kalogeropoulos N . A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225. Pharmaceutics. 2020; 12(2). PMC: 7076693. DOI: 10.3390/pharmaceutics12020188. View

16.

Dalm S, Bakker I, de Blois E, Doeswijk G, Konijnenberg M, Orlandi F . 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2016; 58(2):293-299. DOI: 10.2967/jnumed.116.176636. View

17.

Dobrovolskaia M, Clogston J, Neun B, Hall J, Patri A, McNeil S . Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett. 2008; 8(8):2180-7. PMC: 2613576. DOI: 10.1021/nl0805615. View

18.

Yan Y, Gause K, Kamphuis M, Ang C, OBrien-Simpson N, Lenzo J . Differential roles of the protein corona in the cellular uptake of nanoporous polymer particles by monocyte and macrophage cell lines. ACS Nano. 2013; 7(12):10960-70. DOI: 10.1021/nn404481f. View

19.

Salih S, Elliyanti A, Alkatheeri A, AlYafei F, Almarri B, Khan H . The Role of Molecular Imaging in Personalized Medicine. J Pers Med. 2023; 13(2). PMC: 9959741. DOI: 10.3390/jpm13020369. View

20.

Theodosiou M, Sakellis E, Boukos N, Kusigerski V, Kalska-Szostko B, Efthimiadou E . Iron oxide nanoflowers encapsulated in thermosensitive fluorescent liposomes for hyperthermia treatment of lung adenocarcinoma. Sci Rep. 2022; 12(1):8697. PMC: 9130318. DOI: 10.1038/s41598-022-12687-3. View